TABLE 3.
Patient characteristics of the analysis of second-line chemotherapy
| AEAS# | SAS# | |
| Subjects | 278 | 180 |
| Age years median (range) | 69 (38–85) | 69 (38–83) |
| Sex | ||
| Male | 239 (86.0%) | 154 (85.6%) |
| Female | 39 (14.0%) | 26 (14.4%) |
| Histology | ||
| AdC | 101 (36.3%) | 70 (38.9%) |
| SqCC | 70 (25.2%) | 51 (28.3%) |
| AdSqC | 1 (0.4%) | 1 (0.6%) |
| NSCLC (NOS) | 32 (11.5%) | 14 (7.8%) |
| SmCC | 74 (26.6%) | 44 (24.4%) |
| Pattern of IIPs | ||
| UIP | 146 (52.5%) | 89 (49.4%) |
| Non-UIP | 103 (37.1%) | 66 (36.7%) |
| Unclassified | 29 (10.4%) | 25 (13.9%) |
AEAS: acute exacerbation analysis set; SAS: survival analysis set; AdC: adenocarcinoma; SqCC: squamous cell carcinoma; AdSqC: adenosquamous carcinoma; NSCLC: nonsmall cell lung cancer; NOS: not otherwise specified; SmCC: small cell carcinoma; IIP: idiopathic interstitial pneumonia; UIP: usual interstitial pneumonia. #: AEAS was evaluated for acute exacerbation and objective response by second-line chemotherapy; SAS consisted of patients for which analysable survival information could be obtained.